The most bioactively concentrated material in the hive has been treated as waste. We are building the science to change that permanently — and licence it globally.
Hive dross — the complex residual matrix of wax, pollen, propolis, resins, and honey remaining after honey extraction — contains phenolic compound concentrations that in preliminary LC‑MS analysis demonstrably exceed those found in honey itself. Currently disposed of as organic waste at cost to the industry. We are building the validated fermentation science to transform it into a category‑defining functional ingredient platform.
Innovation often begins by questioning what is taken for granted. The assumption that hive dross is a by‑product of limited value is wrong. The science reveals it is a biological inventory — denser in phenolic compounds than the honey extracted from the same hive.
Conventional extraction methods — aqueous, solvent‑based, supercritical — fail to access the full bioactive complexity locked within hive dross. The solution is not a stronger solvent. It is a biological one.
GLP‑1 (glucagon‑like peptide‑1) receptor agonists are the most discussed pharmaceutical class in the world right now — driving multi‑billion dollar valuations and unprecedented consumer interest in natural analogues. We are not developing a pharmaceutical. We are developing the natural ingredient science that serves that market.
GLP-1 is a gut hormone with powerful metabolic effects: it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Pharmaceutical GLP-1 receptor agonists (semaglutide, liraglutide) have demonstrated unprecedented efficacy for weight loss and metabolic health, creating massive consumer demand for any product that supports natural GLP-1 function.
The connection to hive dross bioactives is mechanistically coherent. Several phenolic compound classes that are expected to be present in significant concentrations in fermented hive dross have demonstrated GLP-1 pathway modulation activity in preclinical studies — including alpha-glucosidase and lipase inhibition (which modulates post-meal glucose and fat absorption), and direct enteroendocrine cell stimulation mechanisms. Mānuka honey itself contains methyl syringate, which has been shown to activate TRPA1 in enteroendocrine cells, significantly suppressing food intake and delaying gastric emptying in murine models.
The SSF programme is specifically designed to maximise the concentration and bioaccessibility of these metabolically active phenolics — transforming bound, inactive precursors into free aglycones with their full biological activity expressed. If the fermentation programme demonstrates the expected phenolic compound profile, hive dross extract will represent an entirely new ingredient category for the metabolic health market: derived from New Zealand's indigenous hive systems, validated by PolySure™, with no direct competitive equivalent.
The phenolic compound profile expected from fermented hive dross maps onto six distinct nutraceutical market categories — each independently large and growing, each supported by existing scientific literature on the specific compound classes involved.
The programme generates IP at multiple levels simultaneously — from process innovation through to ingredient characterisation and biological data. Each layer has independent commercial value and compounds the defensibility of every other layer.
A staged, evidence-gated research programme — each phase building on validated outputs from the last, with go/no-go decision points ensuring capital is deployed only when the science supports progression.